GlassScriptPhysician profile
Lilimae Sotto
NPI 1770245904
$1,329.40
in general payments reported to CMS, 2019-2025
13 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $79.90 · 2024: $768 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $229.10 | 2024-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $197.10 | 2024-2025 | |
| Amgen INC. | $189.79 | 2024 | Parsabiv, Krystexxa, Aranesp |
| Ardelyx, INC. | $139.42 | 2024 | Xphozah 30 Mg, Ibsrela |
| Akebia Therapeutics INC | $121.71 | 2025 | Vafseo |
| Astrazeneca Pharmaceuticals LP | $119.01 | 2023-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $60.56 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $60.13 | 2023 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $56.83 | 2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $54.14 | 2024 | Lupkynis |
| Vifor Pharma, INC. | $46.57 | 2024-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.79 | 2024 | Jardiance |
| Scpharmaceuticals INC. | $25.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilimae Sotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.